Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW5282 in Advanced Solid Tumors
NCT07328217Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GW5282 in solid tumor (advanced stage), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
GW5282
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07328217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328217.